Lv1
50 积分 2023-08-27 加入
Validation and refinement of the 2022 European LeukaemiaNet genetic risk classification of acute myeloid leukaemia patients receiving allogeneic haematopoietic cell transplantation
2天前
已完结
Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis
2天前
已完结
Managing the unmanageable: evidence-driven approaches to real-world patient prototypes of TP53-mutant myelodysplastic neoplasms and acute myeloid leukemia
2天前
已完结
Current myeloproliferative neoplasm scoring systems for clinical practice
5天前
已关闭
Activity of venetoclax-based therapy in chronic myelomonocytic leukemia
15天前
已完结
Philadelphia-chromosome positive acute lymphoblastic leukemia: ten frequently asked questions
1个月前
已完结
Evolving landscape of JAK inhibition in myelofibrosis: monotherapy and combinations
2个月前
已完结
Evolving landscape of JAK inhibition in myelofibrosis: monotherapy and combinations
2个月前
已关闭
Methodological challenges in the development of endpoints for myelofibrosis clinical trials
2个月前
已完结
Enhanced Molecular Response in Myeloproliferative Neoplasms with Complete JAK2V617F Inhibition
2个月前
已完结
皖公网安备34019202002308
